RxDoctor Payments Data

Christopher Sissell, NP

Family · Slidell, LANPI 1730712605

Payments from drug & device makers

$3,952in general payments, 2019–2025

Across 239 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$448
  • Novo Nordisk$423
  • Bayer$421
  • Lilly USA, LLC$345
  • GSK$297
  • Ironwood Pharmaceuticals, Inc$268
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,952100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,952 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$18,046
Medicare patients
129
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin78$102,156
MounjaroTirzepatide58$75,051
OzempicSemaglutide48$74,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$33,678
VraylarCariprazine Hcl12$18,660
TrulicityDulaglutide16$17,989
EliquisApixaban15$14,757
Combivent RespimatIpratropium/Albuterol Sulfate15$7,346
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$4,485
Novolog FlexpenInsulin Aspart12$3,502
Cevimeline Hcl14$2,309
SynthroidLevothyroxine Sodium13$1,772
Atorvastatin Calcium207$1,334
Levothyroxine Sodium138$1,154
Albuterol Sulfate HfaAlbuterol Sulfate44$1,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$82$109,50293 claims
Lilly USA, LLCMounjaro, Trulicity$345$93,04074 claims
Novo NordiskOzempic$423$74,94148 claims
GSKTrelegy Ellipta$297$33,67837 claims
AbbVieVraylar, Synthroid$448$20,43325 claims
PfizerEliquis$95$14,75715 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$1,154138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.

Other family in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →